or read below :
ADED: Ab-dependent enhancement of disease
ADEI: Ab-dependent enhancement of infection
ASLD: Acute self-limiting disease
ASLI: Acute self-limiting infection
IEABs: Infection-enhancing Abs
LRT: Lower respiratory tract
Weak immune activation by glycosylated ASLI- or ASLD-enabling viruses (that occurs, for example, during asymptomatic-mild natural infection) elicits low concentrations of non-neutralizing, short-lived IEABs. Upon subsequent re-exposure to a homologous or antigenically shifted viral lineage these Abs are highly likely to enhance viral uptake by susceptible host cells and contribute to innate immune training of pre-primed NK cells. However, it’s important to note that individuals who contract asymptomatic/ mild infection provoked by a glycosylated ASLVI- or ASLVD-enabling virus can still experience disease. This can occur when re-exposure to the homologous or antigenically shifted viral lineage occurs at a point in time where the short-lived non-neutralizing IEABs are at their very highest level. As these Abs are immature (i.e., non-functional), their titers decline rapidly—they are no longer even detectable after 8 weeks. ADED after asymptomatic/ mild infection is therefore rare and the incidence rate thereof can only significantly increase in case of high viral infectiousness (which will substantially increase the likelihood for re-infection within just a few weeks after the previous asymptomatic-mild infection). In the case of SC-2, high viral infectiousness results from natural selection and dominant propagation of ‘more infectious’ SC-2 variants which is a direct consequence of mass vaccination (as previously explained).
On the other hand, immune priming by glycosylated ASLI- or ASLD-enabling viruses (for example, in people who contract the disease) induces virus-neutralizing Abs as well as non-neutralizing Abs (comprising IEABs). Upon subsequent re-exposure to an antigenically shifted viral lineage binding of the IEABs to a variant-nonspecific site on the virus enhances viral uptake by susceptible host cells. This partially sidelines pre-primed NK cells and calls on cytotoxic CD8+ T cells to clear virus-infected cells, leading to more pronounced symptoms of disease. As the enhanced viral uptake does not usually lead to full drainage of the viral clearance capacity of cytotoxic CD8+ T cells, productive infection will not only enhance training of pre-primed NK cells but also enables priming of ‘new’ Abs directed at the surface protein that is responsible for initiation of infection by the antigenically shifted viral lineage.
This can explain why individuals who contracted disease induced by a glycosylated ASLVI- or ASLVD-enabling virus can still contract disease again (but rarely severe) up to several months after their recovery. This typically occurs when re-infection is caused by an antigenically shifted viral lineage and at a point in time where the naturally induced Ag-specific Abs are still fairly high. The phenomenon can also occur in the case vaccine-induced Abs are confronted with an antigenically shifted viral lineage before they have achieved full-fledged neutralizing capacity. Individuals who got partially vaccinated (e.g., only one shot) with a non-replicating Ab-based viral vaccine and become exposed to an antigenically shifted viral lineage shortly thereafter are prone to this risk.
Finally, strong immune priming by non-replicating Ab-based vaccines elicits high concentrations of both potentially neutralizing and non-neutralizing IEABs. Upon subsequent re-exposure to an antigenically shifted viral lineage the IEABs are highly likely to enhance viral uptake by susceptible host cells in a way that sidelines pre-primed NK cells and increasingly drains the flow capacity of viral clearance by cytotoxic CD8+ T cells (instead of training NK cells). This is likely to not only cause more severe disease and delay recovery, but also to prevent immune priming against the antigenically shifted epitopes (immunologically outcompeted by ‘old’ epitopes that benefit from ‘antigenic sin’). Instead, natural re-exposure to either a homologous or antigenically shifted viral lineage will strongly boost the IEABs for lack of sufficient flow capacity of viral clearance by cytotoxic CD8+ T cells (as a result of deficient NK cell training). In case of re-infection with the same viral variant, this is likely to increase the severity of the disease (due to ADEI) whereas re-exposure to an antigenically shifted viral lineage that is resistant to the potentially infection-neutralizing vaccine-induced Abs (e.g., the more virulent Omicron BA.4 or BA.5 lineages in case of SC-2) will enable boosted IEABs to protect against severe disease (via inhibition of productive trans infection in the LRT).
In the meantime, viral lineages that are resistant to the potentially virulence-neutralizing vaccinal Abs are being selected. Once this has happened, the IEABs will facilitate ADEI-mediated ADED in vaccinees.
Whereas the unvaccinated are experiencing increasing and durable protection from C-19 disease caused by new variants through i) trained innate immunity (which is not susceptible to immune escape!) and ii) priming of new neutralizing Abs against those variants (as ‘antigenic sin’ is mitigated by trained innate immunity!), vaccinees now need to exclusively rely on boosting (as ‘antigenic sin’ is not mitigated by training of pre-primed NK cells) of IEABs (which are prone to immune escape!) to ensure a fragile and provisional protection from severe disease.
Whereas immune training is a blessing, immune drainage is a scourge! That’s why only natural immunity can eventually fully protect you during a pandemic. That’s why Africa will win!
 In case of SC-2, this site is situated within the N-terminal domain of spike protein
 ‘Antigenically shifted’ relates to an antigenic shift in the viral surface protein that is responsible for initiation of infection
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.